Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
Biochemical control
Dose-escalation
Dose–response
Prostate cancer
SBRT
Stereotactic body radiation therapy
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
20
07
2020
revised:
22
09
2020
accepted:
25
09
2020
pubmed:
10
10
2020
medline:
24
4
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
The optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose-response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR) among 4 SBRT dose regimens. In 1908 men with low-risk (50.0%), favorable intermediate-risk (30.9%), and unfavorable intermediate-risk (19.1%) prostate cancer treated with prostate SBRT across 8 institutions from 2003 to 2018, we examined 4 regimens (35 Gy/5 fractions [35/5, n = 265, 13.4%], 36.25 Gy/5 fractions [36.25/5, n = 711, 37.3%], 40 Gy/5 fractions [40/5, n = 684, 35.8%], and 38 Gy/4 fractions [38/4, n = 257, 13.5%]). Between dose groups, we compared PSA decay slope, nadir PSA (nPSA), achievement of nPSA ≤0.2 and ≤0.5 ng/mL, and BCR-free survival (BCRFS). Median follow-up was 72.3 months. Median nPSA was 0.01 ng/mL for 38/4, and 0.17-0.20 ng/mL for 5-fraction regimens (p < 0.0001). The 38/4 cohort demonstrated the steepest PSA decay slope and greater odds of nPSA ≤0.2 ng/mL (both p < 0.0001 vs. all other regimens). BCR occurred in 6.25%, 6.75%, 3.95%, and 8.95% of men treated with 35/5, 36.25/5, 40/5, and 38/4, respectively (p = 0.12), with the highest BCRFS after 40/5 (vs. 35/5 hazard ratio [HR] 0.49, p = 0.026; vs. 36.25/5 HR 0.42, p = 0.0005; vs. 38/4 HR 0.55, p = 0.037) including the entirety of follow-up, but not for 5-year BCRFS (≥93% for all regimens, p ≥ 0.21). Dose-escalation was associated with greater prostate ablation and PSA decay. Dose-escalation to 40/5, but not beyond, was associated with improved BCRFS. Biochemical control remains excellent, and prospective studies will provide clarity on the benefit of dose-escalation.
Sections du résumé
BACKGROUND AND PURPOSE
The optimal dose for prostate stereotactic body radiotherapy (SBRT) is still unknown. This study evaluated the dose-response relationships for prostate-specific antigen (PSA) decay and biochemical recurrence (BCR) among 4 SBRT dose regimens.
MATERIALS AND METHODS
In 1908 men with low-risk (50.0%), favorable intermediate-risk (30.9%), and unfavorable intermediate-risk (19.1%) prostate cancer treated with prostate SBRT across 8 institutions from 2003 to 2018, we examined 4 regimens (35 Gy/5 fractions [35/5, n = 265, 13.4%], 36.25 Gy/5 fractions [36.25/5, n = 711, 37.3%], 40 Gy/5 fractions [40/5, n = 684, 35.8%], and 38 Gy/4 fractions [38/4, n = 257, 13.5%]). Between dose groups, we compared PSA decay slope, nadir PSA (nPSA), achievement of nPSA ≤0.2 and ≤0.5 ng/mL, and BCR-free survival (BCRFS).
RESULTS
Median follow-up was 72.3 months. Median nPSA was 0.01 ng/mL for 38/4, and 0.17-0.20 ng/mL for 5-fraction regimens (p < 0.0001). The 38/4 cohort demonstrated the steepest PSA decay slope and greater odds of nPSA ≤0.2 ng/mL (both p < 0.0001 vs. all other regimens). BCR occurred in 6.25%, 6.75%, 3.95%, and 8.95% of men treated with 35/5, 36.25/5, 40/5, and 38/4, respectively (p = 0.12), with the highest BCRFS after 40/5 (vs. 35/5 hazard ratio [HR] 0.49, p = 0.026; vs. 36.25/5 HR 0.42, p = 0.0005; vs. 38/4 HR 0.55, p = 0.037) including the entirety of follow-up, but not for 5-year BCRFS (≥93% for all regimens, p ≥ 0.21).
CONCLUSION
Dose-escalation was associated with greater prostate ablation and PSA decay. Dose-escalation to 40/5, but not beyond, was associated with improved BCRFS. Biochemical control remains excellent, and prospective studies will provide clarity on the benefit of dose-escalation.
Identifiants
pubmed: 33035622
pii: S0167-8140(20)30828-8
doi: 10.1016/j.radonc.2020.09.053
pmc: PMC7956167
mid: NIHMS1663554
pii:
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-213Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50
pubmed: 16198506
Urology. 1999 Dec;54(6):968-71
pubmed: 10604691
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203
pubmed: 12504054
Urology. 2006 Dec;68(6):1257-62
pubmed: 17141830
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
pubmed: 11429230
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
pubmed: 10192361
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):42-49
pubmed: 30611838
JAMA Oncol. 2018 Jun 14;4(6):e180039
pubmed: 29543933
Front Oncol. 2012 Aug 20;2:81
pubmed: 22934286
Eur Urol Oncol. 2018 Dec;1(6):540-547
pubmed: 31158102
Radiother Oncol. 2018 May;127(2):213-218
pubmed: 29588072
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93
pubmed: 24331654
Radiother Oncol. 2012 Nov;105(2):266-8
pubmed: 23157980
Front Oncol. 2014 Nov 24;4:321
pubmed: 25505732
Radiother Oncol. 2016 Jan;118(1):112-7
pubmed: 26796591
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):628-636
pubmed: 31276777
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):349-355
pubmed: 31780782
JAMA Netw Open. 2020 Feb 5;3(2):e1920471
pubmed: 32022878
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Radiother Oncol. 2020 Aug;149:64-69
pubmed: 32442822
Lancet Oncol. 2014 Apr;15(4):464-73
pubmed: 24581940
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865
pubmed: 29485063
JAMA Oncol. 2015 Oct;1(7):897-906
pubmed: 26181727
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Pract Radiat Oncol. 2016 Jul-Aug;6(4):268-275
pubmed: 26850649
Anticancer Res. 2014 Aug;34(8):4189-93
pubmed: 25075045
Radiother Oncol. 2013 Nov;109(2):217-21
pubmed: 24060175
Ann Oncol. 2012 Sep;23(9):2346-2352
pubmed: 22357249
Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):618-620
pubmed: 31540596
Eur Urol. 2011 Dec;60(6):1133-9
pubmed: 21889832
Front Oncol. 2014 Oct 28;4:301
pubmed: 25389521
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633
pubmed: 30064301
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):299-304
pubmed: 31987958
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789
pubmed: 30959121
Eur Urol Oncol. 2020 Dec;3(6):748-755
pubmed: 31668713
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):334-342
pubmed: 30721721